1633 Broadway
22nd Floor Suite C
New York, NY 10019
United States
212 489 2100
https://www.delcath.com
Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 76
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Gerard J. Michel MBA, MS | CEO & Director | 727.97k | N/A | 1963 |
Ms. Sandra Pennell | Senior VP of Finance and Principal Financial & Accounting Officer | N/A | N/A | 1980 |
Dr. Martha S. Rook Ph.D. | Chief Operating Officer | N/A | N/A | 1970 |
Mr. David Hoffman | General Counsel, Corporate Secretary & Chief Compliance Officer | N/A | N/A | N/A |
Dr. Johnny John M.D. | Senior Vice President of Clinical Operations & Medical Affairs | 472.16k | N/A | 1965 |
Dr. Vojislav Vukovic M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1967 |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Delcath Systems, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.